1. Home
  2. ONC vs TEF Comparison

ONC vs TEF Comparison

Compare ONC & TEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • TEF
  • Stock Information
  • Founded
  • ONC 2010
  • TEF 1924
  • Country
  • ONC Cayman Islands
  • TEF Spain
  • Employees
  • ONC N/A
  • TEF N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • TEF Telecommunications Equipment
  • Sector
  • ONC Health Care
  • TEF Telecommunications
  • Exchange
  • ONC Nasdaq
  • TEF Nasdaq
  • Market Cap
  • ONC 26.9B
  • TEF 29.1B
  • IPO Year
  • ONC N/A
  • TEF 1987
  • Fundamental
  • Price
  • ONC $231.99
  • TEF $4.99
  • Analyst Decision
  • ONC Strong Buy
  • TEF
  • Analyst Count
  • ONC 7
  • TEF 0
  • Target Price
  • ONC $326.43
  • TEF N/A
  • AVG Volume (30 Days)
  • ONC 471.3K
  • TEF 685.5K
  • Earning Date
  • ONC 05-07-2025
  • TEF 05-20-2025
  • Dividend Yield
  • ONC N/A
  • TEF 6.64%
  • EPS Growth
  • ONC N/A
  • TEF N/A
  • EPS
  • ONC N/A
  • TEF N/A
  • Revenue
  • ONC $4,175,868,000.00
  • TEF $42,773,579,059.00
  • Revenue This Year
  • ONC $860.73
  • TEF N/A
  • Revenue Next Year
  • ONC $19.79
  • TEF $0.39
  • P/E Ratio
  • ONC N/A
  • TEF N/A
  • Revenue Growth
  • ONC 51.16
  • TEF 1.63
  • 52 Week Low
  • ONC $141.31
  • TEF $3.89
  • 52 Week High
  • ONC $287.88
  • TEF $5.15
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • TEF 55.58
  • Support Level
  • ONC N/A
  • TEF $4.97
  • Resistance Level
  • ONC N/A
  • TEF $5.12
  • Average True Range (ATR)
  • ONC 0.00
  • TEF 0.06
  • MACD
  • ONC 0.00
  • TEF -0.01
  • Stochastic Oscillator
  • ONC 0.00
  • TEF 50.00

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About TEF Telefonica SA

Telefonica operates mobile and fixed networks in Spain (where it is the incumbent operator), the UK, Germany, Brazil, and Latin American countries. The company derives more than 30% of its revenue from Spain, close to 20% from Germany, and 20% from Brazil. Its UK operations are held through a joint venture with Virgin Media. For several years Telefonica has been simplifying its corporate structure by selling noncore assets.

Share on Social Networks: